

# OBN Christmas Networking & Lecture

**Start Date: Wednesday, December 12,**

**2018 6:00 PM**

**End Date: Wednesday, December 12, 2018 9:00 PM**



Image  
Coming  
Soon

OBN Christmas Lecture - 'A Christmas Wish for Vaccine Research';

Join us for this very special Christmas Lecture by Professor Adrian Hill, Professor of Human Genetics and Director of the Jenner Institute at Oxford University.

Vaccines are recognised as one of the most cost effective approaches to preventing disease outbreaks in humans, and have the potential to ultimately lead to global disease eradication. Professor Hill will kindly share an update on vaccine developments across the range of pathogen types that have a significant impact on global health, particularly in the world's least developed countries.

Further insight will be shared on current research, including the convergence of understanding of the host immune response, disease pathogenesis and pathogen biology in the context of developing effective vaccines and strategies for non-infectious diseases.

Professor Hill will also look beyond the research and development of vaccines, to consider the societal factors that influence the effectiveness of vaccination programmes – perhaps poor communications and information, political systems, family beliefs or parental knowledge and attitudes – or a combination of all of these factors?

Join us for this special update on vaccines development and their practical application and the potential for a fix-all solution, possible limitations and the hurdles to overcome on the journey towards a world free from the risks of pathogen disease.

The lecture will be followed by Christmas Drinks, nibbles and networking with friends and colleagues from across the industry.

More about Professor Adrian Hill:

Adrian Hill trained at Trinity College Dublin and Oxford and is now Professor of Human Genetics and Director of the Jenner Institute at Oxford University, one of the largest non-profit vaccine institutes globally. He leads a research programme on genetic susceptibility to major infectious diseases as well as vaccine design and development. His group discovered the ability of heterologous prime-boost immunisation to induce potent T cell responses pre-clinically and has developed this approach to phase II clinical trials in Africa. He has also pioneered the use of small rapid clinical trials to provide initial safety and immunogenicity with a range of novel vaccine concepts. To date he has led over 50 clinical trials on new malaria vaccines, almost all designed by his laboratory research team.

In 2005 he founded the Jenner Institute which aims to accelerate public sector vaccine development for infectious diseases and links human and veterinary vaccine development, and since 2007 has led or co-led